China News Service, April 1 (Reporter Chen Jing) Gastrointestinal stromal tumor (GIST) is a sarcoma that occurs in the gastrointestinal tract. About 5% to 6% of cases are caused by the PDGFRA D842V mutation.
Such patients have always lacked treatment drugs.
The reporter learned on the 1st that the precision targeted drug Taijihua® (Avatinib tablets, hereinafter referred to as Avatinib) for gastrointestinal stromal tumors (GIST) was approved for marketing by the State Drug Administration of China.
Previously, there was no precision medicine for related types of GIST.
The results of clinical studies showed that the overall remission rate of avatinib reached 62.5%.
Professor Shen Lin, vice president of Peking University Cancer Hospital, said in an interview with reporters that day: “Avatinib has shown very good anti-tumor activity in patients with related types of advanced GIST in China, and its safety and tolerance are good. A Vatinib's approval in China will bring huge survival benefits to these patients."
According to relevant pharmaceutical companies, independent research and development and the introduction of "two-wheel drive" from outside have accelerated their commercialization.
According to reports, this year, the pharmaceutical company’s 4 products will usher in commercialization, in addition to the listing of pratinib and avatinib, its subordinate ivonib (IDH1 inhibitor) and tumor immunotherapy product sugarizumab (PD-L1) are expected to be approved.
Afnib has been included in the "List of New Drugs Urgently Needed in Clinics (Third Batch)" issued by the Center for Drug Evaluation of China National Medical Products Administration.
The company’s chairman and CEO Dr. Jiang Ningjun told reporters in an interview that the company will increase the availability of medicines through innovative payment methods.
On the one hand, it will cooperate with government departments to promote precision treatment products to join medical insurance as soon as possible; on the other hand, it will promote "commercial insurance and other innovative payment methods", such as joint third-party payment companies to launch installment payments and member benefits.
(Finish)